Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaoyu Huang
Observed name:
Yong Zhang
Institutions:
Tianjin Medical University General Hospital,
Affiliated Hospital of Xuzhou Medical College,
Tianjin Medical University
Observed institutions:
Xuzhou Medical College,
Tianjin Medical University General Hospital,
Affiliated Hospital of Xuzhou Medical College,
Tianjin Medical University
ORCID:
0000-0002-0993-6994
Observed ORCID:
0000-0002-0993-6994
OpenAlex ID:
A5100708678
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report
2024
·
Yong Zhang
, Dan Liu
, et al.
·
Journal of Neurology
·
37
Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial
2025
·
Yong Zhang
, Dan Liu
, et al.
·
EClinicalMedicine
·
26
PDF
Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report
2024
·
Zhouao Zhang
, Mingjin Yang
, et al.
·
Therapeutic Advances in Neurological Disorders
·
20
BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares
2026
·
Xiaoyu Huang
, Zhouao Zhang
, et al.
·
Science Advances
·
19
PDF
Increased serum interleukin-41 correlates with disease severity in myasthenia gravis
2024
·
Zhouyi Wang
, Zhouao Zhang
, et al.
·
International Immunopharmacology
·
14
Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis
2025
·
Zhouao Zhang
, Mingjin Yang
, et al.
·
Frontiers in Immunology
·
12
PDF
Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse
2023
·
Xiaoyu Huang
, Hao Li
, et al.
·
Cytokine
·
10
Serum amyloid A facilitates expansion of CD4 + T cell and CD19 + B cell subsets implicated in the severity of myasthenia gravis patients
2024
·
Xiaoyu Huang
, Xueting An
, et al.
·
Journal of Neurochemistry
·
7
Chimeric antigen receptor T cell therapy: a new frontier therapeutic landscape in autoimmune diseases
2025
·
Xueting An
, Xiaoyu Huang
·
Journal of Autoimmunity
·
3
Thymectomy with or without maintenance therapy for myasthenia gravis patients: a tri-center, real-world study
2026
·
Hao Zhang
, Moli Fan
, et al.
·
Therapeutic Advances in Neurological Disorders
·
2
Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker
2025
·
Tiancheng Luo
, Deyou Peng
, et al.
·
Annals of Clinical and Translational Neurology
·
2
PDF
Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study
2026
·
Xueting An
, Lijie Zhu
, et al.
·
Frontiers in Immunology
·
1
PDF
Association of plasma ceramide with stroke-associated pneumonia in acute ischemic stroke
2026
·
Hao Li
, Mengwen Lu
, et al.
·
Frontiers in Immunology
·
1
PDF
Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod: A Case Report
2026
·
Zhouao Zhang
, Xinyan Guo
, et al.
·
The Neurologist
·
1
Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis
2026
·
Zhouyi Wang
, Tiancheng Luo
, et al.
·
Autoimmunity
PDF
Show more works
View as search
Works count:
15
Citation count:
155
H-index:
7
I10-index:
7
Year
Topic
Type